1. Home
  2. SLDB vs VNDA Comparison

SLDB vs VNDA Comparison

Compare SLDB & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$5.46

Market Cap

444.9M

Sector

Health Care

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$8.25

Market Cap

425.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDB
VNDA
Founded
2013
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
444.9M
425.5M
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
SLDB
VNDA
Price
$5.46
$8.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
4
Target Price
$14.82
$13.13
AVG Volume (30 Days)
948.9K
2.8M
Earning Date
11-03-2025
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$212,074,000.00
Revenue This Year
N/A
$12.01
Revenue Next Year
N/A
$21.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.12
52 Week Low
$2.41
$3.81
52 Week High
$7.37
$9.60

Technical Indicators

Market Signals
Indicator
SLDB
VNDA
Relative Strength Index (RSI) 47.29 68.93
Support Level $5.60 $6.87
Resistance Level $5.85 $9.60
Average True Range (ATR) 0.35 0.49
MACD -0.05 0.13
Stochastic Oscillator 25.94 60.87

Price Performance

Historical Comparison
SLDB
VNDA

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: